During the past decade, Retinal & Ophthalmic Cons PC conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 5 clinical trials were completed, i.e. on average, 83.3% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 5 clinical trials were completed. i.e. 500% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Retinal & Ophthalmic Cons PC" #1 collaborator was "National Eye Institute (NEI)" with 2 trials as a collaborator, "National Institutes of Health (NIH)" with 2 trials as a collaborator, "Regeneron Pharmaceuticals" with 2 trials as a collaborator, "Juvenile Diabetes Research Foundation" with 1 trials as a collaborator and "MEDARVA Foundation" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Retinal & Ophthalmic Cons PC" are "Diabetic Macular Edema" (4 trials), "Geographic Atrophy" (3 trials), "Diabetic Retinopathy" (1 trials) and "Symptomatic Vitreomacular Adhesion" (1 trials). Many other conditions were trialed in "Retinal & Ophthalmic Cons PC" in a lesser frequency.

Most popular intervention types in "Retinal & Ophthalmic Cons PC" are "Drug" (7 trials), "Procedure" (3 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Deferred aflibercept" (2 trials), "Deferred laser" (2 trials), "Faricimab" (2 trials), "Lampalizumab" (2 trials) and "Prompt aflibercept" (2 trials). Other intervention names were less common.

The vast majority of trials in "Retinal & Ophthalmic Cons PC" are 8 trials for "All" genders.

Currently, there are NaN active trials in "Retinal & Ophthalmic Cons PC". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Retinal & Ophthalmic Cons PC, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Retinal & Ophthalmic Cons PC, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".